|
1
|
Xiao J, Ma L, Li J, Yin B, Liang J and
Wang J: Primary squamous cell carcinoma of the liver is rare but
hostile: Case series and comprehensive review of the literature.
Cancer Manag Res. 13:829–837. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giorgio A, De Luca M, Gatti P, Matteucci P
and Giorgio V: CEUS LI-RADS categories to distinguish
hepatocellular carcinoma and non-hepatocellular carcinoma
malignancies. Radiology. 296:E121–E122. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kang LM, Yu DP, Zheng Y and Zhou YH:
Primary squamous cell carcinoma of the liver: A case report. World
J Clin Cases. 10:6744–6749. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsieh CB, Chen CJ, Yu JC, Chang TM, Gao HW
and Liu YC: Primary squamous cell carcinoma of the liver arising
from a complex liver cyst: Report of a case. Surg Today.
35:328–331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nieweg O, Slooff MJ and Grond J: A case of
primary squamous cell carcinoma of the liver arising in a solitary
cyst. HPB Surg. 5:203–208. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson JM, Groeschl R, George B, Turaga
KK, Patel PJ, Saeian K and Gamblin TC: Ciliated hepatic cyst
leading to squamous cell carcinoma of the liver-a case report and
review of the literature. Int J Surg Case Rep. 4:972–975. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu KL, Li DY and Jiang CB: Primary
squamous cell carcinoma of the liver associated with
hepatolithiasis: A case report. World J Gastroenterol.
18:5830–5832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arase Y, Endo Y, Hara M, Kumada H, Ikeda K
and Yoshiba A: Hepatic squamous cell carcinoma with hypercalcemia
in liver cirrhosis. Acta Pathol Jpn. 38:643–650. 1988.PubMed/NCBI
|
|
9
|
Shi G, Ye X, Yang F, Wang Z and Ma X:
Hepatic squamous cell carcinoma initially presenting as
cholecystitis misdiagnosed as cholangiocarcinoma: A case report.
Oncol Lett. 29:32024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du Y, Du B, Fang X, Shu M, Zhang Y, Chung
H, Sun Y, Teng J, Visalath P, Qiu H and Cai W: ALT flare predicts
hepatocellular carcinoma among antiviral treated patients with
chronic hepatitis B: A cross-country cohort study. Front Oncol.
10:6152032021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carr BI, Bag HG, Ince V, Akbulut S, Ersan
V, Usta S, Isik B, Ogut Z, Tuncer A and Yilmaz S: A combination of
blood lymphocytes and AST levels distinguishes patients with small
hepatocellular carcinomas from non-cancer patients. J Gastrointest
Cancer. 52:1211–1216. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toyoda H and Johnson PJ: The ALBI score:
From liver function in patients with HCC to a general measure of
liver function. JHEP Rep. 4:1005572022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mazza S, Frigerio C, Alfieri D, Mauro A,
Torello Viera F, Scalvini D, Barteselli C, Sgarlata C, Veronese L,
Bardone M, et al: Prognostic role of basal serum alpha-fetoprotein
in patients with hepatocellular carcinoma suitable for curative
treatment. Medicina (Kaunas). 60:6922024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X and
Tu J: Current status and perspective biomarkers in AFP negative
HCC: Towards screening for and diagnosing hepatocellular carcinoma
at an earlier stage. Pathol Oncol Res. 26:599–603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeng P, Li H, Chen Y, Pei H and Zhang L:
Serum CA199 levels are significantly increased in patients
suffering from liver, lung, and other diseases. Prog Mol Biol
Transl Sci. 162:253–264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong Y, Jing Y, Sun H and Zhou S: The
diagnostic value of contrast-enhanced ultrasound and enhanced CT
combined with tumor markers AFP and CA199 in liver cancer. J
Healthc Eng. 2022:50745712022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu LH, Chen L, Wang QY and Wang YT:
Correlation between HRCT signs and levels of CA125, SCCA, and NSE
for different pathological types of lung cancer. Eur Rev Med
Pharmacol Sci. 27:4162–4168. 2023.PubMed/NCBI
|
|
18
|
Schepens EJA, Al-Mamgani A, Karssemakers
LHE, van den Broek D, van den Brekel MWM and Lopez-Yurda M:
Squamous cell carcinoma antigen in the follow-up of patients with
head and neck cancer. Otolaryngol Head Neck Surg. 170:422–430.
2024. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tony V, Sathyamurthy A, Ramireddy JK,
Iswarya SJ, Gowri SM, Thomas A, Peedicayil A and Ram TS: Role of
squamous cell carcinoma antigen in prognostication, monitoring of
treatment response, and surveillance of locally advanced cervical
carcinoma. J Cancer Res Ther. 19:1236–1240. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song Y, Shi J, Zhang X, Qiao M, Sun Z and
Tian S: Diagnostic value of imaging modalities in primary squamous
cell carcinoma of the liver. J Clin Ultrasound. 51:887–897. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao R, Zhu K, Wang R, Gao J, Cui K, Yu F,
Zhang B and Li S: Primary squamous cell carcinoma of the liver: A
case report and review of the literature. Oncol Lett. 4:1163–1166.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okuda Y, Abe T, Ikeda M, Kurihara K,
Shimizu A, Oshita A, Yonehara S and Hanada K: Curative surgery for
primary squamous cell carcinoma of the liver: A rare case study.
Clin J Gastroenterol. 16:263–269. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XF, Du ZQ, Liu XM and Lv Y: Primary
squamous cell carcinoma of liver: Case series and review of
literatures. Medicine (Baltimore). 94:e8682015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee HL, Fu CK, Chien LY and Chen LM:
Primary squamous cell carcinoma of the liver with good response to
carboplatin and 5-flurouracil: A case report. Medicina (Kaunas).
58:18642022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoo TK, Kim BI, Han EN, Kim DH, Yoo JH,
Lee SJ, Cho YK and Kim HJ: Primary squamous cell carcinoma of the
liver: A case report. Clin Mol Hepatol. 22:177–182. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei DD, Fang JM, Wang HZ, Chen J, Kong S,
Jiang YY and Jiang Y: Perioperative immunotherapy for esophageal
squamous cell carcinoma. Front Immunol. 15:13307852024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Desai A and Peters S: Immunotherapy-based
combinations in metastatic NSCLC. Cancer Treat Rev. 116:1025452023.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daste A, Larroquette M, Gibson N, Lasserre
M and Domblides C: Immunotherapy for head and neck squamous cell
carcinoma: Current status and perspectives. Immunotherapy.
16:187–197. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmults CD, Blitzblau R, Aasi SZ, Alam M,
Andersen JS, Baumann BC, Bordeaux J, Chen PL, Chin R, Contreras CM,
et al: NCCN guidelines® insights: Squamous cell skin
cancer, version 1.2022. J Natl Compr Canc Netw. 19:1382–1394. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang Q, Xu P, Cao F, Wu D and Liu X: PD-1
Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin
for larynx preservation in locally advanced laryngeal and
hypopharyngeal squamous cell carcinoma: A retrospective study.
Cancer Immunol Immunother. 72:4161–4168. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Adkins D, Ley J, Atiq O, Powell S, Spanos
WC, Gitau M, Rigden C, Palka K, Liu J and Oppelt P: Nanoparticle
albumin-bound paclitaxel with cetuximab and carboplatin as
first-line therapy for recurrent or metastatic head and neck
cancer: A single-arm, multicenter, phase 2 trial. Oral Oncol.
115:1051732021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu H, Wang W, Yin J, Song C, Li L and Sun
Z: Efficacy and safety of the PD-1 inhibitor combined with
albumin-bound paclitaxel and nedaplatin in preoperative neoadjuvant
therapy of unresectable stage III lung squamous cell carcinoma.
Drug Des Devel Ther. 16:4269–4277. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng J, Luo G, Yu Y, Ning K and Liu X:
Retrospective assessment of neoadjuvant camrelizumab combined with
induction chemotherapy: Efficacy in laryngeal preservation for
advanced hypopharyngeal and laryngeal squamous cell carcinoma.
Cancer Immunol Immunother. 73:542024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Black CM, Zheng D, Hair GM, Ai L, Wang L,
Goto D, Lerman N, Bidadi B and Hanna GJ: Real-world use of
first-line pembrolizumab + platinum + taxane combination regimens
in recurrent/metastatic head and neck squamous cell carcinoma.
Front Oncol. 14:13480452024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Araki T, Muranushi R, Takagi K, Tanaka H,
Shibuya K, Ando T, Yoshioka I, Hirabayashi K, Yasuda I and Fujii T:
A case of successful conversion surgery for unresectable
gallbladder cancer treated with durvalumab in combination with
gemcitabine plus cisplatin. Clin J Gastroenterol. 18:161–168. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Markham A: Envafolimab: First approval.
Drugs. 82:235–240. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qian Y, Tang L, Yao J, Zhu Y, Zhang Y, Lu
H, Li W, An C and Gui L: Pembrolizumab with chemotherapy for
patients with recurrent or metastatic nasal cavity and paranasal
sinus squamous cell carcinoma: A prospective phase ll study. Clin
Cancer Res. Feb 24–2025.(Epub ahead of print). View Article : Google Scholar
|
|
38
|
Yang Y, Luo X, Dai L, He T, Luo S, Zhou Y,
Wang H, Yan Z, Wang Q and Jin X: A case report of envafolimab in
the treatment of microsatellite stable (MSS) metastatic colon
cancer. Onco Targets Ther. 17:1137–1144. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bhamidipati D and Subbiah V:
Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends
Cancer. 9:828–839. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA,
Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q and
Ajani JA: Association of PD-L1 expression and other variables with
benefit from immune checkpoint inhibition in advanced
gastroesophageal cancer: Systematic review and meta-analysis of 17
phase 3 randomized clinical trials. JAMA Oncol. 8:1456–1465. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bishop JA, Nakaguro M, Weinreb I,
Palsgrove D, Rooper LM, Vandergriff TW, Carlile B, Sorelle JA,
Gagan J and Nagao T: Comprehensive next generation sequencing
reveals that purported primary squamous cell carcinomas of the
parotid gland are genetically heterogeneous. Head Neck Pathol.
18:1062024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen M, Jiang M, Wang X, Shen L and Li J:
Envafolimab-first PD-1/PD-L1 antibody to be administered by
subcutaneous injection for microsatellite instability-high or
deficient mismatch repair advanced solid tumors. Expert Opin Biol
Ther. 22:1227–1232. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahmed J, Das B, Shin S and Chen A:
Challenges and future directions in the management of tumor
mutational burden-high (TMB-H) advanced solid malignancies. Cancers
(Basel). 15:58412023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Altomare NJ, Li Y, Neill C, Hussain M and
VanderWeele DJ: Response to pembrolizumab in advanced prostate
cancer with predictive biomarkers. Oncologist. 30:oyaf0252025.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao L, Zhou Y, Ding J, Qin Z, Zhou H and
Jing X: Primary hepatic squamous cell carcinoma: Case report and
systematic review of the literature. Front Oncol. 13:12299362023.
View Article : Google Scholar : PubMed/NCBI
|
